A Randomized, Double-Blind, Double-Dummy, Multicenter Clinical Trial to Evaluate the Additional Efficacy and Safety of Olmesartan Medoxomil 20mg / Hydrochlorothiazide 12.5mg in the Treatment of Chinese Patients With Mild to Moderate Essential Hypertension, Who Fail to Attain the Blood Pressure Goals With Olmesartan Medoxomil 20mg Monotherapy.
Latest Information Update: 20 Feb 2024
At a glance
- Drugs Olmesartan medoxomil/hydrochlorothiazide (Primary) ; Olmesartan medoxomil
- Indications Essential hypertension
- Focus Therapeutic Use
- Sponsors Daiichi Sankyo Company
Most Recent Events
- 09 Apr 2009 New trial record